FDA panel to review NSAIDs this month

Share this article:

An FDA advisory panel convenes in six days to consider revoking the over-the-counter status of some NSAIDs. Drugstore News reports that the group will meet February 10 to discuss the risks these drugs may pose to heart health. DSN says the group will also discuss whether Pfizer should continue its Celebrex safety study which compares the arthritis pain reliever to ibuprofen and naproxen, since naproxen is considered safer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.